CalciMedica (NASDAQ:CALC) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of CalciMedica (NASDAQ:CALC) from a sell rating to a strong sell rating in a report published on Saturday,Wall Street Zen reports.

CALC has been the subject of several other reports. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Guggenheim began coverage on CalciMedica in a report on Thursday, August 20th. They set a “buy” rating on the stock. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Finally, UBS Group reiterated a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CalciMedica has an average rating of “Hold” and an average price target of $50.00.

CalciMedica Price Performance

Shares of CALC stock opened at $1.98 on Friday. The firm has a fifty day moving average of $3.31 and a two-hundred day moving average of $3.43. The firm has a market cap of $13.52 million, a P/E ratio of -0.29 and a beta of 0.83. CalciMedica has a 1-year low of $1.91 and a 1-year high of $36.00. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58.

CalciMedica (NASDAQ:CALC) last issued its earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.97. As a group, research analysts anticipate that CalciMedica will post -5.25 earnings per share for the current fiscal year.

Insider Buying and Selling at CalciMedica

In other CalciMedica news, Director Fred A. Middleton acquired 49,794 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was acquired at an average price of $4.00 per share, with a total value of $199,176.00. Following the transaction, the director directly owned 212,654 shares in the company, valued at approximately $850,616. This represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 28.25% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CalciMedica

A number of hedge funds and other institutional investors have recently bought and sold shares of CALC. Cetera Investment Advisers grew its holdings in shares of CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares during the last quarter. 180 Wealth Advisors LLC lifted its holdings in shares of CalciMedica by 297.2% in the 1st quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares during the last quarter. Jane Street Group LLC acquired a new position in CalciMedica during the 4th quarter valued at approximately $127,000. Finally, Envestnet Asset Management Inc. boosted its position in CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the period.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.